AR116026A1 - Composición para erradicar helicobacter pylori - Google Patents

Composición para erradicar helicobacter pylori

Info

Publication number
AR116026A1
AR116026A1 ARP190102443A ARP190102443A AR116026A1 AR 116026 A1 AR116026 A1 AR 116026A1 AR P190102443 A ARP190102443 A AR P190102443A AR P190102443 A ARP190102443 A AR P190102443A AR 116026 A1 AR116026 A1 AR 116026A1
Authority
AR
Argentina
Prior art keywords
helicobacter pylori
composition
formula
pharmaceutically acceptable
compound represented
Prior art date
Application number
ARP190102443A
Other languages
English (en)
Inventor
Haneul Jeong
Yu Park
- Kim Jae Min Gyeong
Hyun Ji Kang
Naree Shin
Eun Kyung Kim
Shi Ryu
- Song Geun Seog Young
Ahrong Kim
Kyeongmin Oh
Ji Won Lee
Eun Ji Kim
Dongkyu Kim
Bong Tae Kim
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of AR116026A1 publication Critical patent/AR116026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente se refiere a una composición para erradicar Helicobacter pylori y su uso. La composición de la presente mantiene un pH intragástrico en un cierto nivel o más durante un cierto período de tiempo o más, maximizando así la acción de la amoxicilina y claritromicina para mostrar un excelente efecto sobre erradicación de Helicobacter pylori. Reivindicación 1: Una composición farmacéutica para erradicar Helicobacter pylori, que comprende: un compuesto representado por la fórmula (1), sus isómeros ópticos o sus sales farmacéuticamente aceptables; amoxicilina o sus sales farmacéuticamente aceptables; y claritromicina o sus sales farmacéuticamente aceptables como ingrediente activo. Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, en donde el compuesto representado por la fórmula (1) es un compuesto representado por una fórmula (2).
ARP190102443A 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori AR116026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29

Publications (1)

Publication Number Publication Date
AR116026A1 true AR116026A1 (es) 2021-03-25

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102443A AR116026A1 (es) 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori

Country Status (19)

Country Link
US (1) US20210196685A1 (es)
EP (1) EP3843723A4 (es)
JP (1) JP7189327B2 (es)
KR (1) KR20200026118A (es)
CN (1) CN112638378A (es)
AR (1) AR116026A1 (es)
AU (1) AU2019328903B2 (es)
BR (1) BR112021003578A2 (es)
CA (1) CA3107624C (es)
EA (1) EA202190622A1 (es)
GE (1) GEP20227431B (es)
JO (1) JOP20190201A1 (es)
MX (1) MX2021002278A (es)
MY (1) MY195494A (es)
PH (1) PH12021550385A1 (es)
SG (1) SG11202101920WA (es)
UA (1) UA126993C2 (es)
UY (1) UY38348A (es)
WO (1) WO2020045992A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
EP3955927A4 (en) * 2019-04-18 2023-06-07 Thomas Julius Borody COMPOSITIONS AND METHODS FOR THE TREATMENT, MITIGATION AND PREVENTION OF H. PYLORI INFECTION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
CN101341149B (zh) 2005-12-19 2011-06-08 拉夸里亚创药株式会社 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
MA41730B1 (fr) * 2015-06-08 2019-03-29 Cj Healthcare Corp Utilisation de dérivé de benzimidazole pour l'acidité nocturne
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
UA126993C2 (uk) 2023-03-01
CN112638378A (zh) 2021-04-09
BR112021003578A2 (pt) 2021-05-18
CA3107624C (en) 2023-10-03
GEP20227431B (en) 2022-10-25
JOP20190201A1 (ar) 2020-02-29
SG11202101920WA (en) 2021-04-29
MX2021002278A (es) 2021-08-11
JP2021535910A (ja) 2021-12-23
AU2019328903A1 (en) 2021-04-29
PH12021550385A1 (en) 2021-09-20
KR20200026118A (ko) 2020-03-10
AU2019328903B2 (en) 2023-01-05
EA202190622A1 (ru) 2021-06-10
WO2020045992A1 (en) 2020-03-05
UY38348A (es) 2020-03-31
AU2019328903A8 (en) 2021-05-27
CA3107624A1 (en) 2020-03-05
EP3843723A4 (en) 2022-06-29
JP7189327B2 (ja) 2022-12-13
EP3843723A1 (en) 2021-07-07
MY195494A (en) 2023-01-26
US20210196685A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2017002936A1 (es) Compuestos ciclooctadepsipéptidos, composición veterinaria antihelmíntica, y uso para preparar un medicamento útil contra infección por parásitos o una infestación por parásitos internos o externos en un animal.
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
CL2020000747A1 (es) Formulaciones de niraparib.
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
DOP2012000011A (es) Formulacion farmaceutica
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
CL2012001162A1 (es) Uso de compuestos derivados de acido tetramico para preparar composiciones contra plagas de insectos y/o acaros y/o nematodos mediante aplicacion del principio activo por goteo sobre el suelo.
AR116026A1 (es) Composición para erradicar helicobacter pylori
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO6351683A2 (es) Agente de tratamiento de semillas y metodo para proteger plantas
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
ECSP23088732A (es) Moduladores de trex1
UY31097A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
CO2023003420A2 (es) Nuevos compuestos que tienen actividad inhibitoria sobre el receptor de prostaglandina e2 y usos de los mismos
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
ES2555785T3 (es) Remedio o preventivo para esquizofrenia